

<u>Short Name</u>	<u>Comments</u>	<u>Type</u>	<u>Investigator</u>	<u>Contact</u>
A021703	Randomized Double-blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
WF-1806	Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA2182	A Randomized Phase II Study of De-intensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1613	A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
URCC 16092	A Phase II Study of Exercise and Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG GI004	Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

S0820	A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III- Preventing Adenomas of the Colon with Eflonithine and Sulindac (PACES)	Prevention	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A021502	ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer: A Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EAQ162CD	Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent	Cancer Care Delivery	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EA2165	A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
FC-11	A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients with "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG G1005	Phase II/III Study of Circulating tumOr DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

Merck-4280	MK-4280: A Phase I Trial of MK-4280 (LAG-3 Inhibitor) as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors (Now in Expansion Cohort, All Patients get Pembrolizumab + LAG 3 Inhibitor (MK 4280))	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
CRDF-01E	An Expanded Access Program of Onvansertib in Combination with FOLFIRI and BBEVAcizumab for the Second-Line Treatment of Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC)	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
